BI
KDNY

BVF Inc’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

BVF Inc’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,800,000
Closed -$29.4M – 84
2021
Q4 		$29.4M Buy
+1,800,000
New +$25.6M 1.07% 27
2019
Q4 		– Sell
-202,000
Closed -$1.07M – 62
2019
Q3 		$1.07M Buy
+202,000
New +$1.34M 0.11% 55
2018
Q4 		– Sell
-57,555
Closed -$2.12M – 57
2018
Q3 		$2.12M Sell
57,555
-1,638
-3% -$52.6K 0.19% 52
2018
Q2 		$2.07M Sell
59,193
-102,114
-63% -$3.92M 0.2% 48
2018
Q1 		$7.5M Buy
+161,307
New +$5.9M 0.76% 30
2017
Q4 		– Sell
-36,953
Closed -$1.97M – 45
2017
Q3 		$1.97M Sell
36,953
-23,047
-38% -$1.37M 0.25% 34
2017
Q2 		$3.42M Buy
+60,000
New +$3.01M 0.53% 28
2017
Q1 		– Sell
-149,177
Closed -$8.5M – 32
2016
Q4 		$8.5M Buy
149,177
+48,946
+49% +$2.96M 1.71% 18
2016
Q3 		$6.23M Sell
100,231
-2,490
-2% -$176K 1.17% 22
2016
Q2 		$5.81M Buy
+102,721
New +$6.24M 1.24% 22

Other funds holding KDNY

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BVF Inc's KDNY Position: Q1 2022 in Review

BVF Inc sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q1 2022, closing a stake of 1,800,000 shares — an estimated $29.4M sold.

BVF Inc first reported a position in KDNY in Q2 2016 and held it in 10 quarters. The position peaked at $29.4M in Q4 2021. 105 funds tracked by Wall St. Rank hold KDNY as of Q1 2022.

  • BVF Inc reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • BVF Inc sold 1,800,000 Chinook Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $29.4M.
  • BVF Inc first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2016 and held it in 10 quarters.
  • BVF Inc's Chinook Therapeutics, Inc. Common Stock position peaked at $29.4M in Q4 2021.
  • 105 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q1 2022.

Based on BVF Inc's 13F filing for Q1 2022, filed 16 May 2022.